Logo

Foundation Medicine: Geoffrey Oxnard

Jun 15, 2020

Roche subsidiary Foundation Medicine announced Geoffrey Oxnard has been appointed vice president, global medical lead for the firm's liquid biopsy portfolio, effective immediately. In the role, he'll define research and a liquid biopsy-focused discovery roadmap while investigating novel applications of liquid biopsy approaches to improve cancer research and care.

Oxnard previously served as a thoracic oncologist and clinical investigator at the Dana-Farber Cancer Institute at Harvard Medical School, and he'll continue seeing patients part-time at the institute. His recent research has focused on the clinical application of liquid biopsy technologies to understand drug resistance for selecting targeted therapies and detecting occult cancer. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.